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Understanding perception of risks and benefits is essential in designing good 
risk communication strategies. The primary aim of this study was to evaluate 
the perception of risks and benefits of nine drug classes during pregnancy and 
associations with women’s characteristics. In addition major concerns regarding 
medication use were evaluated. 
Methods
Questionnaires were distributed to pregnant women who attended a Dutch 
obstetric Care facility (first and second line care). Mean perceived risk and 
benefit scores were computed for 9 different drug classes. For each participant 
we computed weighted risk and benefit sum scores with principal component 
analysis. In addition major concerns regarding medication use were evaluated. 
Results
The questionnaire was completed by 136 women (response rate 77%). Pregnant 
women were most concerned about having a child with a birth defect (35%), 
a miscarriage (35%) or that their child developed an allergic disease (23%), 
respectively as a result of drug use. The majority of studied drug classes were 
perceived relatively low in risk and high in benefit. Higher risk scores were reported 
if women were in their first trimesters of pregnancy (p=0.007). Lower benefit scores 
were reported if women were single (p=0.014), smoking (p=0.028), nulliparous 
(p=0.006) or did not have a family history of birth defects (p =0.005).
Conclusion
Pregnant women’s concerns regarding potential drug adverse effects were not 
only focused on congenital birth defects, but included a wider range of adverse 
outcomes. This study showed that most of the studied drug classes were perceived 



































The majority of pregnant women use medication during pregnancy.1 Despite 
increasing availability of information about teratogenic risks, medication use during 
pregnancy still causes uncertainty and concern among pregnant women and their 
health care providers.2,3 
Recent risk perception studies observed that women tend to overestimate 
the magnitude of teratogenic risks.2-14 Though it is difficult to estimate the real 
risk of medication use during pregnancy, unrealistic perception of risk amongst 
pregnant women may lead to poor adherence, discontinuation of treatment and 
even abortion of otherwise wanted and healthy infants.9,14 Counseling enables a 
more balanced decision on the use of medication during pregnancy.8,11,13 However, 
the manner in which information is presented can make a substantial difference 
to people’s responses. For example, providing pregnant women with positively-
framed information will lower risk perceptions significantly.8 In addition, women’s 
perception of the benefits of mediation use may have a major influence on the 
acceptance of risks. 
In previous risk perception studies, risk was often presented as the probability of 
having a child with a congenital malformation.4,12 Though congenital malformations 
are severe adverse effects, medication use during pregnancy has been associated 
with a broader spectrum of disorders than congenital malformations alone.15-17 
However, studies about a broader variety of concerns among women as a result 
of medication use during pregnancy is absent. 
The primary aim of this study is to evaluate the perception of risks and 
benefits of medication use during pregnancy and associations with women’s 
socio-demographical characteristics. In addition we evaluate the major concerns 
amongst pregnant women regarding medication use.
Methods
Study design, setting and study population 
Questionnaires were distributed to pregnant women who attended an obstetric 
care facility (Medical Center Leeuwarden) in the netherlands (both first and second 
line care).  Women were included in the study during the 1st of May until the 30th of 
June 2013. Questionnaires were distributed to all pregnant women in the waiting 
room of the obstetric care facility, regardless of their health status or antenatal care 
needs. Since waiting times were often extensive, questionnaires could easily be 
finished by the participants. In Dutch healthcare, first line care is easily accessible 
and patients can contact first line care providers, without a referral. Second line 
care is specialist care in hospitals where pregnant women need a referral from a 



































In this study an anonymous self-reported questionnaire was developed and 
used. The questionnaire consisted of four parts to collect data on 1) general 
characteristics, 2) medication use during pregnancy and information sources used 
3) major concerns related to medication use, and 4) perceived risks and benefits 
of medication use during pregnancy.
A group of 10 pregnant women recruited from the gynaecology department 
in the Medical Center Leeuwarden, a 800-bed secondary teaching hospital, were 
asked to pre-test a prefinal version of the questionnaire. They were interviewed 
if the questionnaire was clear to them and if they had comments or suggestions 
to state them in the text box given at the end of the questionnaire. no specific 
comments were returned, so we decided that the pretest was good and no further 
changes were required. 
Part 1. General characteristics
Socio-demographic variables included in the questionnaire were age, education, 
marital status, duration of the pregnancy, gravidity, parity, status of employment 
and attending first or second line care facility. Lifestyle variables that were examined 
were the use of alcohol and smoking during pregnancy.
Part 2. Medication use during pregnancy and information sources used
Respondents were asked whether and which medication they used with and 
without a prescription during pregnancy. Classes of drugs were presented, 
including examples of generic and trade names. Presented drug classes were 
paracetamol, nSAIDs, vitamins other than folic acid and vitamin D, drugs against 
a cold, acid suppressive medication, antibiotics, antifungal medication, drugs 
against nausea and vomiting, sedatives/anxiolytics, anti-asthma medication, anti-
diabetes medication, medication against high blood pressure and homeopathic 
medication.18
Folic acid and vitamin D are vitamins which are advised in the netherlands during 
pregnancy.19 Therefore, women who only used these vitamins are categorized as 
non-medication users. When prenatal vitamins were reported, we considered 
them as multivitamins designed for pregnant women containing more and/or other 
vitamins than folic acid and vitamin D. 
Women were asked if they obtained information about medication before and 
during pregnancy. Commonly used sources of information were listed: internet, 
gynaecologist, general practitioner (GP), pharmacist, midwife, package information 


































Part 3. Measurements of concerns
Women were asked to rate their level of concern about having a miscarriage, 
preterm birth, complicated delivery, child with a birth defect or a child with a 
low gestational age as a result of medication use during pregnancy. In addition 
women were asked to rate their level of concern about having a child with 
memory/learning problems, behavioral problems or an allergic disease. These 
events are not evident at birth, but are associated with medication use during 
pregnancy in literature.15-17,20  Women could rate there level of concern with a 
score from 1 to 5 on a 5 point scale (Table 1).20
Part 4. Perceived risks and benefits of medication use during pregnancy 
Different studies on risk perception proposed that risk is dependent on the 
expectancy of the probability of an event and the beliefs about the potential 
harm.12,21-26 In this study, women were asked to rate the probability and severity 
of an event occurring due to exposure to several drug classes on a 7-point Likert 
scale (Table 1).26 For each drug class, examples of generic and trade names were 
given. Risk scores were constructed by multiplication of the measures of perceived 
probability and severity. A square-root extraction was performed to make the risk 
scores comparable with the benefit scores.22 To get information on the perceived 
table 1. Questions and scales on which concerns related to medication use, probability, 
severity and benefits were rated
Concerns
To what extent are you concerned that there is an increased probability that this event  occurs as a 
result of medication use?  
1 = never concerned, 2 = sometimes concerned, 3 = neutral, 4 = often concerned and 5 = always 
concerned 
Probability
How likely do you think that an accident or unfortunate event involving this drug  occurs?
1 =  Very unlikely; 7 = Very likely
Severity
If an accident or unfortunate event involving this drug occurred, to what extent are the 
harmful effects to baby and/or mother?
1= Very mild harm; 7= Very serious harm
Benefits
How beneficial do you consider this drug or item to be for pregnant women and their  babies?


































benefits of medication during pregnancy, women were asked to rate the benefits 
of the drug classes on a scale from 1 to 7 (Table 1).
Statistical analysis
Percentages were computed for the respondents that were concerned or very 
concerned (scored 4 or 5 on the concern scale) for the matters involving medication 
use during pregnancy.  Means and standard deviations were computed for the 
perceived risk (probability times severity score) and benefit scores of the different 
drug classes. We also calculated Pearson’s correlation coefficients between risk 
and benefit scores for each separate drug class. 
Separate principal component analyses (PCA) were performed on the 9 
different drugs on the risk scale and on the 9 different drugs on the benefit scale, 
respectively.  PCA was used to construct weighted risk and benefit sum scores using 
the loadings of the first principal component as weights.27,28  With this construction, 
the weighted sum scores represent unbiased estimates of standardized values 
on a latent variable (e.g. ‘overall perceived benefit’). The loadings are used as 
weights because the size of each loading indicates the degree to which a variable 
represents an aspect of the underlying latent variable. Given the relatively high 
proportion of variance explained by each first principal component, we take their 
respective latent variables to represent ‘overall’ risk and benefit, respectively. 
The first principal component on the risk scale explained 58.5% of the variance, 
whereas the first principal component of the benefit scale explained 53.4% of the 
variance. The Barlett’s test of sphericity and the Kaiser-Meyer-olkin (KMo) test 
were performed to test if the number of significant correlations was sufficient to 
perform PCA.27 Bartlett’s test of sphericity was significant (p<0.001) for the 3 scales. 
KMo statistic showed that a factor analysis was appropriate for the risk and benefit 
scales (0.833 and 0.859 respectively).28 
Linear regression models were used to examine associations between maternal 
age, education level and the weighted risk and benefit sum score. Student t-test was 
performed to assess differences in the weighted risk and benefit sum score for the 
different general characteristics, medication use and acquirement of information. 
All analyses were performed using the software SPSS for windows (version 21).
results
Response and General Characteristics
During the two months the questionnaire was distributed, 177 women were 
informed about the study. The questionnaire was returned by 136 women (77%). 
Data on general characteristics of the study population was provided in Table 2. 
The mean age of the respondents was 30.8 (SD ± 5) years. Most of the 


































table 2. General Characteristics of study population (n = 136)
Characteristics Number (%)
Mean age ± SD (years) 30.8 ± 5.0
Marital status:   Married / Cohabiting 126 (92.6)
Duration Pregnancy*  First trimester 16 (13.8)
     Second trimester 36 (31.0)




Previous miscarriages 41 (30.1)
Presence of birth defects in first degree family 26 (19.1)
  
Education Low level of education 21 (15.4)
  Medium level of education 53 (39.0)
  High level of education 62 (45.6)
Working status 
 not working in healthcare sector 78 (57.4)
  Working in healthcare sector 31 (22.8)
  not working 27 (19.9)
Attended  first line care facility 24 (17.6)
  Second line care facility 111 (81.6)
Smoking during pregnancy 15 (11.0)
  
Alcohol cons. during pregnancy 0 (0.0)
* Information on trimester of pregnancy is missing for 2 respondents.
of pregnancy. The women included in the study were approximately similar in 
characteristics as the general Dutch population of pregnant women with respect 


































population) and education level (high education 40% general population vs 42% 
in study population).29,30 
Medication use
Most of the women (82.2%) had used medication during pregnancy (table 3). 
Paracetamol was used most commonly during pregnancy (42%). other common 
used drugs were vitamins (21%), acid suppressive medication (25%) and antibiotics 
(10%). of the respondents 56 (48%) reported to have used folic acid and/or vitamin 
D during pregnancy. Information about medication was obtained by 76 women 
(67%). Most used information sources were the internet, PIL and GP.
table 3. Reported medication use during pregnancy (n=136)
Type of medication Total (%)* On prescription (%) OTC (%)
Total 97 (82.2) 66 (48.5) 69 (58.5)
 Paracetamol 49 (41.5) 11 (8.1) 41 (34.7)
  Vitamins other than folic acid  
and vitamin D
25 (21.2) - 25 (21.2)
 Acid suppressive medication 30 (25.4) 10 (7.4) 21 (17.8)
  Antacids 24 (20.3) 4 (2.9) 21 (17.8)
  H2-antagonists/PPIs 6 (4.4) 6 (4.4) -
 Antibiotics 11 (8.1) 11 (8.1) -
 nSAIDs 1 (0.7) 1 (0.7) 0 (0.0)
  Topical drugs against vaginal  
fungal infections
7 (5.1) 7 (5.1) 1 (0.8)
 Anti-depressive medication 5 (4.2) 5 (4.2) -
 Cardiovascular medication 8 (5.9) 8 (5.9) -
 Anti-diabetes medication 4 (2.9) 4 (2.9) -
 Anti-allergy medication** 6 (4.4) 6 (4.4) -
 Laxatives 6 (4.4) 6 (4.4) -
 Fe- supplementation 10 (8.5) 10 (8.5) -
 Thyrax 9 (7.6) 9 (7.6) -
 Anti-cold medication 10 (8.5) - 10 (8.5)
 other 22 (16.2) 15 (11.0) 10 (7.4)
OTC= Over The Counter, PPIs= Proton Pump Inhibitors
* Women could have used both on prescription and OTC medication, hence the number for total medication 
use is lower than the sum of on prescription and OTC medication use. 



































Pregnant women were most concerned (score 4 or 5 on the concern score) about 
having a child with a congenital birth defect (35%), having a miscarriage (35%) or 
having a child with an increased risk for an allergic disease (23%), respectively as 
a result of their drug use. The different concerns pregnant women had regarding 
medication use during pregnancy are presented in Figure 1. 
Perceptions of risk and benefits 
Highest risk scores were reported for antidepressants, sedatives/anxiolytics and 
nSAIDs, respectively. Highest benefit scores were reported for antibiotics, drugs 
for fungal infections and antacids. Mean risk and benefit scores, including Pearson 
correlation coefficients are presented in Figure 2. Risks and benefit scores were 
significantly inversely correlated for most of the drug classes. When mean risk 
scores were plotted against mean benefit scores almost half of the drug classes 
were perceived as low in risk and high in benefit (figure 3).  In addition figure 3 
showed that the spread of mean values of the different drugs on the risk scale is 
higher (from 1.9 to 5.3) than the spread of mean values of the different drugs on 
the benefit scale (from 3.3 to 4.7). 
Analysis of the weighted sum risk score showed that women in the first two 
trimesters of pregnancy perceived significantly higher risks of medication use 
(p=0.007). The remaining characteristics education, maternal age,  employed in 
health care sector, nulliparity, previous miscarriages, smoking during pregnancy 
and use of medication showed no statistically significant differences in weighted risk 
sum scores. Lower benefit scores of medication use were perceived if women were 
single (p = 0.014), smoking during pregnancy (p = 0.028), nulliparous (p = 0.006) 
or did not have a family history of birth defects (p = 0.005). 
figure 1. Percentage of women that were either often or always concerned about different 


































figure 2. Means of the perceived risk and perceived benefits of different medication groups 




Women were most concerned that medication use during pregnancy could result 
in a child with a congenital birth defect, a miscarriage or a child that develops 
an allergic disease. Most of the drug classes were perceived relatively low in risk 
and high in benefit. only antidepressants, sedatives/anxiolytics and nSAIDs were 
perceived as high risk medication. Women had lower risk perceptions during early 
trimesters of pregnancy. Lower benefit scores were perceived if women were single, 



































our study is the first to investigate the perceived risk-benefit balance with regard 
to medication use during pregnancy. Another major strength of our study is the 
method of inclusion. In previous risk perception studies women were invited to 
participate in the studies when visiting websites containing pregnancy related 
information. To our opinion this could have led to selection bias and the inclusion 
of more concerned women. Since, women were included independently of their 
information seeking behavior in current study, the influence of this type of selection 
bias will likely be less. Importantly, the distribution of general characteristics were 
comparable between the study population and the Dutch pregnant population 
as a whole. Further, all participants were asked to fill out the questionnaire while 
they were pregnant. With this approach the outcome of the pregnancy couldn’t 
have influenced their risk perceptions. In addition, recall bias regarding medication 
use will  be minimal when asked during pregnancy.31 Another strength of our 
study is the questionnaire design, because information about medication use 
was obtained with both open and closed questions. It has been reported that 
figure 3. Scatterplot of risk and benefit means divided into quadrants low risk and low 
benefit, low risk and high benefit, high risk and high benefit, high risk and low benefit. 



































prevalence estimates are higher when questions include indications or specific 
drugs when compared to open-ended questions.32 A final strength of the study 
was the use of the weighted risk and benefit sum scores. The weighted sum 
scores represent unbiased estimates of standardized values on a latent variable 
(e.g. ‘overall perceived benefit’). 
Apart from these strengths, potential limitations need to be discussed. We 
included all pregnant women that were attending first and second line care 
facilities, regardless of their health status or antenatal care, to reduce the risk of 
sampling bias. Although every pregnant woman living in the netherlands can take 
a prenatal screening the majority of our study population consisted out of women 
that came for a routine follow-up with an obstetrician. We could therefore not 
exclude the possibility that the study population differed from the general birthing 
population. nevertheless, as stated above, the distribution of age and level of 
education were similar between the study population and the general birthing 
population in the netherlands.29,30 Though the response rate was rather high for 
a questionnaire study (77%) and associations were significant in most evaluations, 
the total number of participants was low. Due to the low statistical power, we 
could not perform comparisons between women prescribed the specific drugs and 
women who did not. Such analyses would show how actual users balance the risks 
and benefits of a specific drug and would represent the potential non-compliance 
in that population. In addition we compared risks and benefits for drug classes 
instead of specific drugs within the drug classes. This made our questions more 
comprehensible by pregnant women, however since there may be variation within 
each drug classes, findings can not be interpreted for specific drugs. 
Interpretation and comparison with literature
Women were most concerned that medication use during pregnancy could result 
in a child with a birth defect, a miscarriage or a child who develops an allergic 
disease. Though different studies investigated the different worries of pregnant 
women in general20, this is the first study that reports women’s concerns regarding 
medication use during pregnancy. 
Different studies reported that risks associated with medication use were 
perceived higher than actual risks.2-14 However it has been considered that the 
relativeness of risk perceptions is more interesting than the mean risk perceptions 
itself.12 From the different drug classes, sedatives and antidepressants were 
perceived highest in risk and paracetamol and antacids were perceived lowest. This 
is in accordance with findings from a recent study in norway.12 Though  pregnant 
women overestimate teratogenic risk of medication use2-14, this study showed that 
women perceive benefits of medication use as well. When risks were balanced with 
benefits most of the drugs were perceived relatively low in risk and high in benefit. 


































confounding of risks and benefits in women’s minds may implicate that it is possible 
to change the risk perception by changing the perception of benefits of medication 
use.35 The variance of perceived risks was higher than the variance of perceived 
benefits between the different drug classes (Figure 3). That risk scores were rated 
with more extreme values than the benefit scores may indicate that women have 
more difficulty rating the benefits of medication use than the risks. Including more 
information about the benefits of medication use during counseling may play an 
important role in lowering risk perceptions amongst pregnant women.33 
Analyses of the weighted risk sum score showed that women perceived 
higher risks during the first two trimesters of pregnancy than women in the third 
trimester of pregnancy. In the first trimester, organogenesis takes place and risks 
on spontaneous abortion and congenital anomalies are highest. However, recently 
it has been stated that exposures during third trimester can also have negative 
implications for the child.15,16 
Analyses of the weighted benefit sum score showed that women perceived 
lower benefit scores if they were single, smoking or nulliparous. Since no earlier 
research focused on the potential benefits of medication use during pregnancy, 
we can only speculate about potential explanations. Single women lack the option 
to discuss their concerns and fears with a partner, which may contribute to a more 
cautious attitude towards medication use during pregnancy and lower perceived 
benefit scores. nulliparous women may also have a more cautious attitude towards 
medication use during pregnancy, since they never experienced a pregnancy 
before. In addition, a previous study performed in norway found that nulliparous 
women perceived higher risks of medication use during pregnancy.12 Women who 
smoked during pregnancy more often tend to have a low socioeconomic status. In 
addition the vision of these women on a healthy pregnancy may be different, since 
these women keep maintaining an unhealthy lifestyle even if they are pregnant. 
They may therefore not fully comprehend the potential benefits of medication 
use during pregnancy. Women with a family history of birth defects, perceived 
higher benefit scores of medication use during pregnancy. These women may 
have more knowledge about medication use during pregnancy, especially about 
the benefits. For example, they may be aware that folic acid supplementation may 
prevent certain birth defects. 
ConClusion
This study shows that concerns regarding medication use during pregnancy are not 
restricted to having a child with a congenital birth defect only. Though pregnant 
women overestimate teratogenic risk of medication use, most of the drugs were 
perceived relatively low in risk and high in benefit. Health care providers can take 
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